1. ACT-13 DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA: A FIRST-IN-HUMAN, PHASE 1 STUDY. (3rd December 2022) Authors: Yoshiki, Arakawa; Reardon, David; Narita, Yoshitaka; Goldlust, Samuel; Anstass, George; McMullen, Dragana; Dow, Edward; Seki, Masataka; Furuta, Yudai; Song, Gregory; Colman, Howard Journal: Neuro-oncology advances Issue: Volume 4(2022)Supplement 3 Page Start: iii8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ACTR-64. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/mTOR INHIBITOR GDC-0084 IN GBM PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE (MGMT) PROMOTER STATUS. (11th November 2019) Authors: Wen, Patrick; DeGroot, John; Battiste, James; Goldlust, Samuel; Garner, James; Simpson, Jeremy; Kijlstra, Jelle; Olivero, Alan; Cloughesy, Timothy Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL. (14th November 2022) Authors: Liau, Linda M; Ashkan, Keyoumars; Brem, Steven; Campian, Jian; Trusheim, John; Iwamoto, Fabio; Tran, David; Anstass, George; Cobbs, Charles; Heth, Jason; Salacz, Michael; D'Andre, Stacy; Aiken, Robert; Moshel, Yaron; Nam, JooYeon; Pillainayagam, Clement; Wagner, Stephanie; Walter, Kevin; Chaudary... Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 7 Page Start: vii66 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. CTNI-09. TRIDENT PHASE 3 TRIAL (EF-32): FIRST-LINE TUMOR TREATING FIELDS (TTFields; 200 KHZ) CONCOMITANT WITH CHEMO-RADIATION, FOLLOWED BY MAINTENANCE TTFIELDS/TEMOZOLOMIDE IN NEWLY-DIAGNOSED GLIOBLASTOMA. (12th November 2021) Authors: Shi, Wenyin; Kleinberg, Lawrence; Jeyapalan, Suriya; Goldlust, Samuel; Nagpal, Seema; Combs, Stephanie; Roberge, David; Nishikawa, Ryo; Reardon, David; Grossman, Rachel; Glas, Martin Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. CTNI-17. A PHASE 1 WITH DOSE EXPANSION/PHASE 2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA. (12th November 2021) Authors: Odia, Yazmin; Wen, Patrick; Mehta, Minesh; Colman, Howard; Dunbar, Erin; Butowski, Nicholas; Harrison, Rebecca; Schulder, Michael; Boockvar, John; Chow, Frances; Kumthekar, Priya; Mason, Warren; Venur, Vyshak; Plotkin, Scott; Lassman, Andrew; Duic, Paul; Tamir, Sharon; Li, Kai; Liu, Yang; Mundy, ... Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. CTNI-27. MULTI-CENTER, PHASE 2 STUDY EVALUATING THE PHARMACOKINETICS, SAFETY AND PRELIMINARY EFFICACY OF PAXALISIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH UNMETHYLATED GLIOBLASTOMA (GBM). (14th November 2022) Authors: Wen, Patrick Y; de Groot, John; Battiste, James; Goldlust, Samuel; Damek, Denise; Ellingson, Benjamin; Garner, James; Friend, John; Simpson, Jeremy; Olivero, Alan; Cloughesy, Timothy Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 7 Page Start: vii76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. CTNI-44. INTERIM RESULTS OF PHASE 2 STUDY TO EVALUATE PI3K/mTOR INHIBITOR PAXALISIB (GDC-0084) GIVEN TO NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE PROMOTER. (9th November 2020) Authors: Wen, Patrick; de Groot, John; Battiste, James; Goldlust, Samuel; Damek, Denise; Garner, James; Simpson, Jeremy; Olivero, Alan; Cloughesy, Timothy Journal: Neuro-oncology Issue: Volume 22(2020)Supplement 2 Page Start: ii52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. CTNI-74. PHASE 3 TRIDENT TRIAL: CONCOMITANT RADIATION THERAPY (RT) AND TEMOZOLOMIDE +/- TUMOR TREATING FIELDS (TTFIELDS) IN NEWLY DIAGNOSED GLIOBLASTOMA. (9th November 2020) Authors: Shi, Wenyin; Kleinberg, Lawrence; Jeyapalan, Suriya A; Goldlust, Samuel; Nagpal, Seema; Combs, Stephanie E; Roberge, David; Nishigawa, Ryo; Grossman, Rachel; Glas, Martin Journal: Neuro-oncology Issue: Volume 22(2020)Supplement 2 Page Start: ii59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. CTNI-77. EF-19, A POST-APPROVAL REGISTRY STUDY OF TUMOR TREATING FIELDS (TTFIELDS) IN RECURRENT GLIOBLASTOMA (rGBM). (9th November 2020) Authors: Zhu, Jay-Jiguang; O'Donnell, Robert T; Goldlust, Samuel; Ram, Zvi Journal: Neuro-oncology Issue: Volume 22(2020)Supplement 2 Page Start: ii60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. RTID-03. DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA: A FIRST-IN-HUMAN, PHASE 1 STUDY. (14th November 2022) Authors: Reardon, David A; Narita, Yoshitaka; Arakawa, Yoshiki; Goldlust, Samuel; Anstass, George; McMullen, Dragana; Dow, Edward; Seki, Masataka; Furuta, Yudai; Song, Gregory; Colman, Howard Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 7 Page Start: vii249 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗